Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug.

Authors: Emil Kuriakose; Katherine Vandris; Y Lynn Wang; William Chow; Amy V Jones; Paul Christos; Nicholas C P Cross; Richard T Silver
Journal: Haematologica Date: 2011-11-18 Impact factor: 9.941

Review 6. Busulphan treatment of polycythaemia vera.

Authors: I Brodsky
Journal: Br J Haematol Date: 1982-09 Impact factor: 6.998

7. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.

Authors: R Hehlmann; H Heimpel; J Hasford; H J Kolb; H Pralle; D K Hossfeld; W Queisser; H Löffler; B Heinze; A Georgii
Journal: Blood Date: 1993-07-15 Impact factor: 22.113

8. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.

Authors: R Hehlmann; H Heimpel; J Hasford; H J Kolb; H Pralle; D K Hossfeld; W Queisser; H Löffler; A Hochhaus; B Heinze
Journal: Blood Date: 1994-12-15 Impact factor: 22.113

9. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.

Authors: P D Berk; J D Goldberg; P B Donovan; S M Fruchtman; N I Berlin; L R Wasserman
Journal: Semin Hematol Date: 1986-04 Impact factor: 3.851

10. Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.).

Authors:
Journal: Br J Cancer Date: 1981-07 Impact factor: 7.640

12 in total

Review 1. What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Authors: Paola Guglielmelli; Giada Rotunno; Annalisa Pacilli; Alessandro Maria Vannucchi
Journal: Curr Hematol Malig Rep Date: 2015-12 Impact factor: 3.952

2. Effect of busulfan on JAK2V617F allele burden.

Authors: Maria Luigia Randi; Claudia Santarossa; Edoardo Peroni; Elisabetta Cosi; Elena Duner; Irene Bertozzi; Fabrizio Fabris
Journal: Haematologica Date: 2014-01-03 Impact factor: 9.941

Review 3. Myeloproliferative neoplasm stem cells.

Authors: Adam J Mead; Ann Mullally
Journal: Blood Date: 2017-02-03 Impact factor: 22.113

Review 4. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.

Authors: Andreas Reiter; Claire Harrison
Journal: Curr Hematol Malig Rep Date: 2016-10 Impact factor: 3.952

5. Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven Retinopathy.

Authors: Lauren A Dalvin; Timothy W Olsen; Sophie J Bakri; Kristen McCullough; Ayalew Tefferi; Aref Al-Kali
Journal: Am J Ophthalmol Case Rep Date: 2022-04-21

6. Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience.

Authors: K Begna; A Abdelatif; S Schwager; C Hanson; A Pardanani; A Tefferi
Journal: Blood Cancer J Date: 2016-05-27 Impact factor: 11.037

Review 7. Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches.

Authors: Karl Haslam; Stephen E Langabeer
Journal: Biomed Res Int Date: 2016-10-20 Impact factor: 3.411

8. Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.

Authors: Margherita Perricone; Francesca Palandri; Emanuela Ottaviani; Mario Angelini; Laura Bagli; Enrica Bellesia; Meris Donati; Donato Gemmati; Patrizia Zucchini; Stefania Mancini; Valentina Marchica; Serena Trubini; Giovanna De Matteis; Silvia Di Zacomo; Mosè Favarato; Annamaria Fioroni; Caterina Bolzonella; Giorgia Maccari; Filippo Navaglia; Daniela Gatti; Luisa Toffolatti; Linda Orlandi; Vèronique Laloux; Marco Manfrini; Piero Galieni; Barbara Giannini; Alessia Tieghi; Sara Barulli; Maria Luisa Serino; Monica Maccaferri; Anna Rita Scortechini; Nicola Giuliani; Daniele Vallisa; Massimiliano Bonifacio; Patrizia Accorsi; Cristina Salbe; Vinicio Fazio; Milena Gusella; Eleonora Toffoletti; Marzia Salvucci; Mirija Svaldi; Filippo Gherlinzoni; Francesca Cassavia; Francesco Orsini; Giovanni Martinelli
Journal: Oncotarget Date: 2017-05-16

Review 9. Essential thrombocythemia treatment algorithm 2018.

Authors: Ayalew Tefferi; Alessandro M Vannucchi; Tiziano Barbui
Journal: Blood Cancer J Date: 2018-01-10 Impact factor: 11.037

Review 10. Polycythemia vera treatment algorithm 2018.

Authors: Ayalew Tefferi; Alessandro M Vannucchi; Tiziano Barbui
Journal: Blood Cancer J Date: 2018-01-10 Impact factor: 11.037